Change in the total number of shares and votes in Recipharm AB (publ)

In February 2015, the number of shares in Recipharm AB (publ) (“Recipharm”) has increased by 2,915,544 shares of series B, corresponding to 2,915,544 votes. The increase in the number of shares and votes results from conversion of convertible bonds issue in connection with the acquisition of Corvette Pharmaceutical Services Group, completed on 1 October 2015. Following the conversion of convertible bonds as set out above there are no outstanding convertible bonds in Recipharm.  

As of 27 February 2015, the total number of shares in Recipharm amounts to 45,719,418, divided into 12,685,716 shares of series A and 33,033,702 shares of series B. The total number of votes in Recipharm as of 27 February 2014 amounts to 159,890,862.

This information is published in accordance with Chapter 4, Section 9 of the Swedish Financial Instruments Trading Act (SFS 1991:980).

For further information please visit www.recipharm.com or contact:

Thomas Eldered, CEO, thomas.eldered@recipharm.com, telephone: +46 8 602 52 10

Björn Westberg, CFO, bjorn.westberg@recipharm.com, telephone: +46 8 602 46 20

This information is published in accordance with the Swedish Securities Market Act, the Swedish Financial Instruments Trading Act and/or the regulations of Nasdaq Stockholm. This information was submitted for publication on 27 February 2015, at 08:00 am CET.

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52 00, Fax 46 8 81 87 03

www.recipharm.com

About Us

About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 6.0 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com

Subscribe

Documents & Links